Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
20 Sep 24
10-Q
2024 Q2
Quarterly report
6 Aug 24
8-K
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
6 Aug 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jul 24
8-K
Departure of Directors or Certain Officers
27 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 24
8-K
Regulation FD Disclosure
3 Jun 24
8-K
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
23 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
9 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Departure of Directors or Certain Officers
12 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
28 Feb 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
8-K
Regulation FD Disclosure
4 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7 Nov 23
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
3 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Oct 23
424B5
Prospectus supplement for primary offering
17 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
10 Jul 23
8-K
Regulation FD Disclosure
27 Jun 23
8-K
Entry into a Material Definitive Agreement
23 Jun 23
ARS
2022 FY
Annual report to shareholders
15 Jun 23
DEF 14A
Definitive proxy
15 Jun 23
DEFA14A
Additional proxy soliciting materials
23 May 23
8-K
Entry into a Material Definitive Agreement
23 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
9 May 23
8-K
Regulation FD Disclosure
20 Apr 23
Latest ownership filings
4
Change in insider ownership
13 Jun 24
4
James Peyer
13 Jun 24
4
Bob Holmen
13 Jun 24
4
Jessie English
13 Jun 24
4
Kristian Humer
13 Jun 24
4
WILLIAM R RINGO
13 Jun 24
4
THOMAS G RICKS
13 Jun 24
4
Deneen Vojta
13 Jun 24
3
David G Gaiero
16 May 24
SC 13D/A
Newtyn Management, LLC
7 Mar 24
4
der Horst Edward van
16 Feb 24
4
John Celebi
16 Feb 24
4
Erin Colgan
16 Feb 24
SC 13D/A
Newtyn Management, LLC
13 Feb 24
SC 13D
Newtyn Management, LLC
3 Nov 23
4
Stephanie Krebs
2 Nov 23
3
Stephanie Krebs
2 Nov 23
4
John Celebi
13 Sep 23
4
Patrick Stephen Gallagher
11 Sep 23
4
der Horst Edward van
11 Sep 23
4
John Celebi
11 Sep 23
4
Erin Colgan
11 Sep 23
SC 13G/A
Cambrian BioPharma Inc
4 Aug 23
4
Change in insider ownership
2 Aug 23
4
James Peyer
2 Aug 23
4
Change in insider ownership
12 Jul 23
4
James Peyer
12 Jul 23
4
Bob Holmen
12 Jul 23
4
Deneen Vojta
12 Jul 23
4
Jessie English
12 Jul 23
4
Kristian Humer
12 Jul 23
4
Samuel Broder
12 Jul 23
4
THOMAS G RICKS
12 Jul 23
4
WILLIAM R RINGO
12 Jul 23
4
Christian Angermayer
2 Jun 23
SC 13D/A
Apeiron Investment Group Ltd.
2 Jun 23
SC 13D/A
Apeiron Investment Group Ltd.
23 May 23
4/A
Erin Colgan
29 Mar 23
4/A
John Celebi
29 Mar 23
4/A
Patrick Stephen Gallagher
29 Mar 23